The FDA has granted a breakthrough therapy designation to CPX-351 (Vyxeos) as a treatment for patients with therapy-related acute myeloid leukemia... Read More >>
The FDA has expanded the label of ibrutinib (Imbruvica) to include overall survival results in treatment-naive patients with chronic lymphocytic... Read More >>
Featured Programs
Expert Perspectives: Management of Acute Myeloid Leukemia
Ruben A. Mesa, MD, FACP, moderates this discussion with Rafael Bejar, MD, PhD; Elias Jabbour, MD; and Rami Komrokji, MD. These experts in hematology and oncology discuss the pathways involved in leukemic transformation, risk-adjusted approaches to treatment, and supportive care in acute myeloid leukemia.
View Now
Expert Perspectives on the Management of Chronic Myeloid Leukemia
Jorge E. Cortes, MD, moderates this discussion on recent advances in the treatment of chronic myeloid leukemia. The expert panel; Harry P. Erba, MD, PhD; Kevin Kelly, MD, PhD; Javier Pinilla-Ibarz, MD, PhD; and David S. Snyder, MD, FACP, review the latest data and provide perspective on practical application.
View Now
Immunotherapy and Oncology

Anti-Angiogenic Therapy in Lung and GI Cancers

Anti-Angiogenic Therapy in Lung and GI Cancers
Mark Socinski, MD, moderates this OncLive Peer Exchange panel discussion on modern use of anti-angiogenic therapy. The experts in gastrointestinal and lung cancers include Johanna C. Bendell, MD; Edward Garon, MD; Roy Herbst, MD; Yelena Y. Janjigian, MD; and Manish Shah, MD.
View Now
Vincent T. DeVita Jr MD
In The Death of Cancer, written by Vincent T. DeVita Jr, MD, a pioneering oncologist reveals, after 50 years on the front lines of medicine, why the war on cancer is winnable, and how to get there.